Related Experiment Video
Updated: Jul 6, 2026
06:08
Transcranial Pulse Stimulation for Alzheimer's Patients
Published on: April 4, 2025
Script representation in patients with Alzheimer's disease.
Philippe Allain1, Didier Le Gall, Céline Foucher
1Centre Mémoire de Ressources et de Recherche, Centre Hospitalier Universitaire, Angers, France. phallain@chu-angers.fr
Summary
Alzheimer's disease (AD) patients showed significant impairments in understanding event sequences and categorizing actions compared to healthy elderly individuals. These findings highlight deficits in both event order and meaning processing in AD.
Area of Science:
- Cognitive Neuroscience
- Neuropsychology
Background:
- Script representation is crucial for daily functioning.
- Alzheimer's disease (AD) is known to affect cognitive processes.
Purpose of the Study:
- To investigate script representation deficits in Alzheimer's disease (AD) patients.
- To compare AD patients with healthy elderly (HE) subjects on script-based tasks.
Main Methods:
- 26 AD patients and 31 HE subjects sorted and sequenced actions belonging to eight scripts.
- Tasks involved actions varying in centrality and distinctiveness.
- Three conditions tested: scripts with headers (SH), without headers (SwH), and with distractor headers (SDH).
Main Results:
- AD patients performed significantly worse than HE subjects across all conditions.
- AD patients made more sequencing errors than HE subjects.
- AD patients exhibited more sorting errors for all action types (central, distinctive, and combined).
Conclusions:
- Alzheimer's disease impairs both the sequential (syntactic) and meaning-based (semantic) aspects of script representation.
- These findings contribute to understanding the cognitive underpinnings of AD's impact on daily activities.
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.